Zai Lab Demonstrates Robust, Durable Responses In Phase 1 Clinical Study Of Zocilurtatug Pelitecan In Pre-Treated Participants With Extensive-Stage Small Cell Lung Cancer Across Six Dose Groups

Author: Benzinga Newsdesk | October 24, 2025 08:10am

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clinical trial of zocilurtatug pelitecan (zoci), formerly known as ZL-1310, (NCT06179069) demonstrating robust and durable responses in heavily pre-treated patients with extensive-stage small cell lung cancer (ES-SCLC). This data will be presented as an oral presentation and was included as part of the press program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025, in Boston, Massachusetts.

The presentation includes updated results from the Phase 1 monotherapy dose escalation and dose expansion portion of the study from 115 patients across six dose cohorts (0.8 mg/kg, 1.2 mg/kg, 1.6 mg/kg, 2.0 mg/kg, 2.4 mg/kg, and 2.8 mg/kg) as of the data cut-off date of September 15, 2025. 102 patients had the opportunity of at least one post-baseline tumor assessment per Response Evaluation Criteria in Solid Tumors version 1:1 (RECIST v1.1).

All patients in this multicenter study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. Of all patients, 44% had failed two prior lines of therapy, making this a highly pretreated population with limited therapeutic options. Eleven patients received a prior DLL3 bi-specific antibody. A total of 32% of patients had brain metastases at baseline. This study included patients in the United States, Spain, and China.

Posted In: ZLAB